|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MT1H |
Gene summary for MT1H |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MT1H | Gene ID | 4496 |
| Gene name | metallothionein 1H | |
| Gene Alias | MT-0 | |
| Cytomap | 16q13 | |
| Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | A0A140VJP7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4496 | MT1H | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.06e-04 | 3.18e-01 | -0.1808 |
| 4496 | MT1H | HTA11_347_2000001011 | Human | Colorectum | AD | 1.25e-02 | 1.87e-01 | -0.1954 |
| 4496 | MT1H | HTA11_411_2000001011 | Human | Colorectum | SER | 2.71e-02 | 5.15e-01 | -0.2602 |
| 4496 | MT1H | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.78e-04 | 3.96e-01 | -0.1207 |
| 4496 | MT1H | HTA11_866_2000001011 | Human | Colorectum | AD | 3.42e-06 | 3.15e-01 | -0.1001 |
| 4496 | MT1H | HTA11_2992_2000001011 | Human | Colorectum | SER | 5.47e-03 | 5.04e-01 | -0.1706 |
| 4496 | MT1H | HTA11_5212_2000001011 | Human | Colorectum | AD | 8.84e-17 | 1.36e+00 | -0.2061 |
| 4496 | MT1H | HTA11_546_2000001011 | Human | Colorectum | AD | 1.60e-03 | 3.79e-01 | -0.0842 |
| 4496 | MT1H | P4T-E | Human | Esophagus | ESCC | 2.90e-03 | 4.61e-01 | 0.1323 |
| 4496 | MT1H | P5T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.07e-01 | 0.1327 |
| 4496 | MT1H | P20T-E | Human | Esophagus | ESCC | 2.18e-13 | 3.32e-01 | 0.1124 |
| 4496 | MT1H | P24T-E | Human | Esophagus | ESCC | 1.78e-03 | 2.48e-01 | 0.1287 |
| 4496 | MT1H | P27T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.74e-01 | 0.1055 |
| 4496 | MT1H | P31T-E | Human | Esophagus | ESCC | 3.60e-13 | 8.11e-01 | 0.1251 |
| 4496 | MT1H | P80T-E | Human | Esophagus | ESCC | 1.30e-10 | 7.46e-01 | 0.155 |
| 4496 | MT1H | P104T-E | Human | Esophagus | ESCC | 3.26e-14 | 1.26e+00 | 0.0931 |
| 4496 | MT1H | P107T-E | Human | Esophagus | ESCC | 4.67e-06 | 1.72e-01 | 0.171 |
| 4496 | MT1H | P128T-E | Human | Esophagus | ESCC | 9.84e-83 | 5.75e+00 | 0.1241 |
| 4496 | MT1H | P130T-E | Human | Esophagus | ESCC | 3.02e-26 | 2.25e+00 | 0.1676 |
| 4496 | MT1H | Pat01-B | Human | Stomach | GC | 5.44e-03 | 2.34e-01 | 0.5754 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001003831 | Stomach | CAG | response to metal ion | 34/552 | 373/18723 | 6.12e-09 | 8.53e-07 | 34 |
| GO:00975013 | Stomach | CAG | stress response to metal ion | 7/552 | 19/18723 | 6.90e-07 | 4.81e-05 | 7 |
| GO:00712763 | Stomach | CAG | cellular response to cadmium ion | 9/552 | 40/18723 | 1.91e-06 | 1.11e-04 | 9 |
| GO:00102733 | Stomach | CAG | detoxification of copper ion | 6/552 | 15/18723 | 2.55e-06 | 1.35e-04 | 6 |
| GO:19901693 | Stomach | CAG | stress response to copper ion | 6/552 | 15/18723 | 2.55e-06 | 1.35e-04 | 6 |
| GO:00712413 | Stomach | CAG | cellular response to inorganic substance | 21/552 | 226/18723 | 3.70e-06 | 1.78e-04 | 21 |
| GO:00466863 | Stomach | CAG | response to cadmium ion | 11/552 | 68/18723 | 4.43e-06 | 2.09e-04 | 11 |
| GO:00712483 | Stomach | CAG | cellular response to metal ion | 19/552 | 197/18723 | 6.23e-06 | 2.75e-04 | 19 |
| GO:00616873 | Stomach | CAG | detoxification of inorganic compound | 6/552 | 18/18723 | 8.77e-06 | 3.76e-04 | 6 |
| GO:00100433 | Stomach | CAG | response to zinc ion | 9/552 | 58/18723 | 4.63e-05 | 1.45e-03 | 9 |
| GO:00712943 | Stomach | CAG | cellular response to zinc ion | 6/552 | 24/18723 | 5.47e-05 | 1.60e-03 | 6 |
| GO:00466883 | Stomach | CAG | response to copper ion | 7/552 | 42/18723 | 2.05e-04 | 4.32e-03 | 7 |
| GO:00712803 | Stomach | CAG | cellular response to copper ion | 5/552 | 28/18723 | 1.23e-03 | 1.63e-02 | 5 |
| GO:000688211 | Stomach | CAG | cellular zinc ion homeostasis | 5/552 | 38/18723 | 4.92e-03 | 4.24e-02 | 5 |
| GO:005506911 | Stomach | CAG | zinc ion homeostasis | 5/552 | 40/18723 | 6.14e-03 | 4.88e-02 | 5 |
| GO:009875426 | Thyroid | goiters | detoxification | 19/497 | 152/18723 | 2.24e-08 | 2.16e-06 | 19 |
| GO:000963628 | Thyroid | goiters | response to toxic substance | 21/497 | 262/18723 | 7.42e-06 | 3.22e-04 | 21 |
| GO:004668626 | Thyroid | goiters | response to cadmium ion | 8/497 | 68/18723 | 4.26e-04 | 1.04e-02 | 8 |
| GO:007127618 | Thyroid | goiters | cellular response to cadmium ion | 6/497 | 40/18723 | 6.05e-04 | 1.44e-02 | 6 |
| GO:004668819 | Thyroid | goiters | response to copper ion | 6/497 | 42/18723 | 7.91e-04 | 1.74e-02 | 6 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04978 | Stomach | GC | Mineral absorption | 15/708 | 60/8465 | 8.88e-05 | 9.80e-04 | 6.90e-04 | 15 |
| hsa049781 | Stomach | GC | Mineral absorption | 15/708 | 60/8465 | 8.88e-05 | 9.80e-04 | 6.90e-04 | 15 |
| hsa049784 | Stomach | CSG | Mineral absorption | 11/633 | 60/8465 | 4.40e-03 | 2.53e-02 | 1.82e-02 | 11 |
| hsa049785 | Stomach | CSG | Mineral absorption | 11/633 | 60/8465 | 4.40e-03 | 2.53e-02 | 1.82e-02 | 11 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MT1H | SNV | Missense_Mutation | c.112N>A | p.Pro38Thr | p.P38T | P80294 | protein_coding | deleterious(0.03) | benign(0.27) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MT1H | SNV | Missense_Mutation | c.22N>A | p.Glu8Lys | p.E8K | P80294 | protein_coding | tolerated(0.15) | benign(0.019) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| MT1H | SNV | Missense_Mutation | c.95N>A | p.Ser32Asn | p.S32N | P80294 | protein_coding | tolerated(0.06) | benign(0.218) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MT1H | SNV | Missense_Mutation | c.158C>T | p.Ala53Val | p.A53V | P80294 | protein_coding | deleterious(0.04) | benign(0) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MT1H | SNV | Missense_Mutation | c.158C>G | p.Ala53Gly | p.A53G | P80294 | protein_coding | tolerated(0.14) | benign(0.072) | TCGA-75-6214-01 | Lung | lung adenocarcinoma | Female | Unknown | III/IV | Unknown | Unknown | PD | |
| MT1H | SNV | Missense_Mutation | c.94A>T | p.Ser32Cys | p.S32C | P80294 | protein_coding | deleterious(0) | possibly_damaging(0.865) | TCGA-NJ-A4YI-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| MT1H | SNV | Missense_Mutation | novel | c.88N>G | p.Lys30Glu | p.K30E | P80294 | protein_coding | deleterious(0.02) | probably_damaging(0.945) | TCGA-21-1082-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MT1H | SNV | Missense_Mutation | c.83C>A | p.Ser28Tyr | p.S28Y | P80294 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-56-8628-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MT1H | SNV | Missense_Mutation | novel | c.101G>A | p.Cys34Tyr | p.C34Y | P80294 | protein_coding | deleterious(0.04) | probably_damaging(0.995) | TCGA-77-7465-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MT1H | SNV | Missense_Mutation | novel | c.37N>C | p.Cys13Arg | p.C13R | P80294 | protein_coding | deleterious(0) | possibly_damaging(0.848) | TCGA-CN-A498-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4496 | MT1H | NA | GLUCOCORTICOID | 11713267 | ||
| 4496 | MT1H | NA | CISPLATIN | CISPLATIN | 10422815 | |
| 4496 | MT1H | NA | H2O2 | 8385930 | ||
| 4496 | MT1H | NA | STREPTOZOTOCIN | STREPTOZOCIN | 9176863 | |
| 4496 | MT1H | NA | SELENIUM | 3309208 | ||
| 4496 | MT1H | NA | HORMONES | 15196976 | ||
| 4496 | MT1H | NA | 6-AN | 11835189 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |